Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.

被引：0

作者：

Reck, Martin

Kaiser, Rolf

Mellemgaard, Anders

Douillard, Jean Yves

Orlov, Sergey

Krzakowski, Maciej Jerzy

Von Pawel, Joachim

Gottfried, Maya

Bondarenko, Igor

Liao, Meilin

Barrueco, Jose

Gaschler-Markefski, Birgit

Novello, Silvia

机构：

[1] Grosshansdorf Hosp, Dept Thorac Oncol, Grosshansdorf, Germany

[2] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany

[3] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark

[4] Ctr Rene Gauducheau, Dept Med Oncol, F-44035 Nantes, France

[5] St Petersburg State Med Univ, Dept Thorac Oncol, St Petersburg, Russia

[6] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland

[7] Asklepios Fachkliniken Gauting, Pneumol Clin, Munich, Germany

[8] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel

[9] Municipal Inst Dnipropetrov, Dnepropetrovsk, Ukraine

[10] Shandong Prov Chest Hosp, Shanghai, Peoples R China

[11] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA

[12] Univ Turin, Dept Oncol, Turin, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA8011

引用

页数：1

共 50 条

[31] A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.
Schlumberger, Martin
Newbold, Kate
Hasan, Baktiar
Marreaud, Sandrine
Assele, Samson
Licitra, Lisa F.
Schoffski, Patrick
Leboulleux, Sophie
Locati, Laura
Godbert, Yann
Rohmer, Vincent
Jarzab, Barbara
Domenico, Salvatore
Bechter, Oliver Edgar
Zanetta, Sylvie
Capdevila, Jaume
Kapiteijn, Ellen
Bastholt, Lars
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
Yan Song
Bo Zhang
Dao Xin
Xiaoge Kou
Zhenbo Tan
Shu Zhang
Meili Sun
Jin Zhou
Min Fan
Ming Zhang
Yongxiang Song
Suyi Li
Yuan Yuan
Wu Zhuang
Jingdong Zhang
Li Zhang
Hao Jiang
Kangsheng Gu
Huangyang Ye
Ying Ke
Jing Li
Qingyu Wang
Jun Zhu
Jing Huang
Nature Medicine, 2023, 29 : 473 - 482
[33] First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
Song, Yan
Zhang, Bo
Xin, Dao
Kou, Xiaoge
Tan, Zhenbo
Zhang, Shu
Sun, Meili
Zhou, Jin
Fan, Min
Zhang, Ming
Song, Yongxiang
Li, Suyi
Yuan, Yuan
Zhuang, Wu
Zhang, Jingdong
Zhang, Li
Jiang, Hao
Gu, Kangsheng
Ye, Huangyang
Ke, Ying
Li, Jing
Wang, Qingyu
Zhu, Jun
Huang, Jing
NATURE MEDICINE, 2023, 29 (02) : 473 - 482
[34] Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.
Sama, Ashwin Reddy
Denlinger, Crystal Shereen
Vogel, Arndt
He, Aiwu Ruth
Bousmans, Nathalie
Zhang, Wei
Walgren, Richard A.
Valle, Juan W.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[35] Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
Seckl, Michael J.
Ottensmeier, Christian H.
Cullen, Michael
Schmid, Peter
Ngai, Yenting
Muthukumar, Dakshinamoorthy
Thompson, Joyce
Harden, Susan
Middleton, Gary
Fife, Kate M.
Crosse, Barbara
Taylor, Paul
Nash, Stephen
Hackshaw, Allan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1506 - +
[36] Randomized, double-blind, phase 3 trial of first-line pembrolizumab plus platinum doublet chemotherapy (chemo) lenvatinib in patients (pts) with metastatic nonsquamous non small-cell lung cancer (NSCLC): LEAP-006.
Hui, Rina
Nishio, Makoto
Reck, Martin
Rodriguez-Abreu, Delvys
Fouad, Tamer M.
Flaim, Doreen
Yin, Lina
Dang, Thao
Herbst, Roy S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[37] Phase III, Randomized, Double-Blind Trial of Bavituximab Plus Docetaxel in Previously Treated Stage IIIb/IV Non-Squamous NSCLC (SUNRISE)
Spigel, David R.
Shan, Joseph
Chiappori, Alberto
Keilholz, Ulrich
Reck, Martin
Edelman, Martin
Domine, Manuel
Park, Keunchil
Jang, Tae Won
Su, Wu-Chou
Sanborn, Rachel E.
Horn, Leora
Heist, Rebecca
Mainwaring, Paul
Gerber, David E.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S427 - S427
[38] Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)
Belani, C.
Ramalingam, S.
Kalemkerian, G.
Mok, T.
Rosell, R.
Ahn, M. J.
Sun, L.
Gates, M.
Lubiniecki, G. M.
Govindan, R.
EJC SUPPLEMENTS, 2009, 7 (02): : 507 - 507
[39] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
Jotte, Robert M.
Socinski, Mark A.
Reck, Martin
Papadimitrakopoulou, Vassiliki
West, Howard J.
Mok, Tony
Sandler, Alan
Mocci, Simonetta
Coleman, Shelley
Asakawa, Takashi
Cappuzzo, Federico
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
[40] PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY IN SECOND-LINE ADVANCED NSCLC PATIENTS
Mellemgaard, Anders
Douillard, Jean-Yves
Novello, Silvia
Kaiser, Rolf
Orlov, Sergey
Krzakowski, Maciej
Von Pawel, Joachim
Gottfried, Maya
Bondarenko, Igor
Liao, Meilin
Barrueco, Jose
Gaschler-Markefski, Birgit
Griebsch, Ingolf
Reck, Martin
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S153

← 1 2 3 4 5 →